Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 12/20 | 0.37 |
| ▸ | CDK2 | P24941 | 10/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.34 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5083616 | 0.88 | CDK1 (0.34) | CDK1CDK2CDK5DYRK1ACCNB1 | |
| SCHEMBL5082371 | 0.88 | CDK1 (0.33) | CDK1 | |
| SCHEMBL5082996 | 0.83 | CDK1 (0.35) | CDK1CDK2CDK5CSNK1DCLK2 | |
| SCHEMBL5083038 | 0.82 | CDK1 (0.41) | CDK1CDK2CDK5CSNK1DCLK2 | |
| SCHEMBL5083003 | 0.82 | CCNE2 (0.31) | CDK2CCNE1CCNE2 | |
| SCHEMBL5083699 | 0.74 | CDK1 (0.41) | CDK1CDK2CDK5CSNK1DCLK2 | |
| SCHEMBL5085999 | 0.72 | CDK1 (0.33) | CDK1CDK2CDK5CSNK1DCLK2 | |
| SCHEMBL5085976 | 0.71 | HPRT1 (0.32) | CDK1CDK2CDK5CCNE1CCNB1 | |
| SCHEMBL5086113 | 0.71 | HPRT1 (0.35) | CDK1CDK2CDK5CCNE1CCNB1 | |
| SCHEMBL5080082 | 0.70 | CCNB2 (0.31) | CDK1CDK2CDK5CCNE1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | CDK1 704/4885CDK2 339/4885CDK5 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.